metabolic inactivation rates, and serum fall-off interaction of isoniazid and para-amino-salicylic acid in man. 
addition to these side effects common to vasodilators, minoxidil has been implicated in the development of pulmonary hypertension.4 7 Since vasodilators are useful not only in the treatment of hypertension but also in the management of refractory congestive heart failure, angina, and even cardiogenic shock, it is important to evaluate the hemodynamic effects of such agents on the pulmonary as well as systemic circulation. The present study was designed to compare mean pulmonary artery and capillary wedge pressures, cardiac output, and pulmonary artery resistance before and after acute (5 day) and chronic (2 month) minoxidil administration in severely hypertensive humans. Electrocardiographic abnormalities were seen in six patients and cardiomegaly on chest X-ray in four. The endogenous creatinine clearance ranged from 54-106 ml/min (mean = 77 ml/min) prior to the initiation of minoxidil therapy. Five of the seven patients were studied at all of the specified protocol periods.
Methods

Protocol of Study
Patients entered the study period following at least a two week interval during which antihypertensive medications were limited to hydralazine, propranolol, and hydrochlorothiazide. While in the hospital, dietary intake was controlled at 2 g sodium, 3 g potassium, 100 g protein, and 1800 cal/ day. On day 1 of the study, those patients who were receiving hydralazine had the medication discontinued. Fixed doses of hydrochlorothiazide (50 mg every 12 hours) and propranolol (40 mg every 6 hours) were then initiated to minimize the sodium retention and reflex tachycardia anticipated during subsequent minoxidil therapy.
The protocol was divided into three distinct periods of study. Patients were initially admitted for ten days which included a five day equilibration period, during which the patients received only hydrochlorothiazide and propranolol (control), followed by five days during which the effective minoxidil dose was established (acute study). After the first hospitalization, patients were discharged on the same effective dose of minoxidil, propranolol, and hydrochlorothiazide. Two months later, the patients were readmitted for a five day period (chronic study).
Catheterization
Hemodynamic data were obtained in the cardiac laboratory on the fifth day of each study period (control, acute, and chronic). The patients received their antihypertensive medications as previously described on the morning of catheterization. A #7 French, triple-lumen Swan-Ganz catheter was inserted into an antecubital vein and placed in the right pulmonary artery under fluoroscopy. Cannulation of the right femoral artery was performed immediately thereafter with catheter placement in the distal abdominal aorta. The patients were allowed to equilibrate for 5-15 min until mean arterial pressure stabilized. Mean pressures were obtained from the abdominal aorta (ASP), right atrium (R1A7P), pulmonary artery (PAP) and pulmonary capillary wedge position (PCWP) with Statham strain gauges (P23 GB). Cardiac output was determined by either the Fick or indicator dilution technique (Lexington Instruments automated cardiac output computer and clinical densitometer, model RLD). Indocyanine green was injected into the pulmonary artery with arterial blood sampling from the distal abdominal aorta. The method used for cardiac output measurements for the control, acute, and 5d   2m  C  5d  2m  C  5d  2m  C  5d  2m  C   5d   2m   1  140  110  110  5  5  7  17  15  16  12  10  11  60  66  70  2  123  105  2  3  18  18  5  7  72  64  3  140  122  119  2  2  2  15  16  15  5  6  5  62  68  66  4  140  105  105-1  2  1  13  14  10  2  4  3  78  78  76  5  129   92  96  1  1  0  9  8  9  3  2  3  70  88  70  6  148  109  112  3  4  3  18  16  17  9  7  8  60  65  65  7  127  87  3  3  13  13  4  3 Cardiac output, heart rate, and stroke volume data are depicted in figure 3. Significant increases in mean cardiac output were observed in hoth the acute (29%) and chronic (22%) study. A significant increase in heart rate was observed acutely even with concurrent propranolol therapy. However, at the chronic study, heart rate was not significantly greater than control. Stroke volume was significantly increased compared to the control value both acutely and chronically. The mean increase in heart rate was 10% acutely and 3% chronically, whereas the mean increase in stroke volume was 16% acutely and 19% chronically. Therefore, changes in stroke volume had a greater effect on cardiac output than did changes in heart rate.
The significant decreases in both peripheral vascular and pulmonary arteriolar resistance in response to five days and two months of minoxidil therapy are displayed in table 3. As demonstrated in figure 4 , the change in peripheral vascular resistance from control was significantly greater than the change in pulmonary arteriolar resistance from control, both in the five day and two month studies. The changes of both peripheral vascular and pulmonary arteriolar resistance were significantly correlated with their initial control levels (r = -0.890 and -0.838, respectively) as shown in figure 5 . The The efficacy of minoxidil in reducing severely elevated blood pressure has been confirmed in the present study. All of the patients had been severely hypertensive and refractory to maximally tolerated doses of several antihypertensive drugs but were well controlled with the combination of minoxidil, propranolol, and hydrochlorothiazide. Although our patients were not selected for the absence of a history of congestive heart failure, they all demonstrated low-normal pulmonary capillary wedge and pulmonary artery pressures initially which did not change with two months of minoxidil therapy. An increase in cardiac output in response to minoxidil has been observed by several authors.1 2, 7, 15 This was noted in the present study as well, even though patients were treated concurrently with propranolol. Furthermore, the relatively greater increase in stroke volume when compared to heart rate during minoxidil treatment appeared to account for this increase in cardiac output. By significantly lowering arterial blood pressure and therefore afterload, minoxidil would enhance ventricular efficiency and increase both stroke volume and cardiac output without an increase in cardiac work.
Minoxidil exerts a greater effect on peripheral vascular resistance than pulmonary arteriolar resistance. It is not surprising that the decrease in peripheral resistance was proportionately greater than that of pulmonary arteriolar resistance, as indicated in figure 4 . One might anticipate this differential response because of the greater number of muscular resistance arterioles in the peripheral system as compared to the capacitance system of the pulmonary vascular bed. Since the effect of minoxidil would be expected to be greatest on the active resistance vessels, the greatest dilatory response or decrease in resistance would be expected to occur in those vessels with the highest initial resistance.
The relationship depicted in figure 5 substantiates this hypothesis both in the peripheral and pulmonary vascular beds. However, the fact that this relationship was not observed at the 2 month study may well reflect an autoregulatory response.
In the normal pulmonary circuit, increases in flow do not increase pressure because of the tremendous capacitance of the pulmonary system. The present study has shown that the decrease in resistance induced by minoxidil in the peripheral system is greater than the comparable decrease in the pulmonary system (fig. 4) . Furthermore, cardiac output increases in response to minoxidil therapy ( fig. 3) . In a hypertensive patient treated with minoxidil, a reduction in peripheral resistance occurs that is sufficient to produce normal arterial pressure despite this increase in cardiac output. However, should the pulmonary resistance decrease less than cardiac output increases, an increase in pulmonary arterial pressure might result in response to minoxidil. Indeed, Tarazi has reported this phenomenon in four patients studied during minoxidil therapy without propranolol. Two of these patients were subsequently treated with propranolol and a decrease in cardiac output and pulmonary artery pressure occurred.7 In the present study, all patients were treated with propranolol at the initiation of minoxidil therapy and although an increase in mean cardiac output of 29% was noted, pulmonary artery pressure remained normal.
From the hemodynamic data obtained in the present study, Observations of cardiac output, heart rate, and stroke volume before and during minoxidil therapy. 5 2
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one can anticipate that in certain patients minoxidil therapy might be complicated by increases in the PAP.
Patients with pre-existing chronic pulmonary hypertension and primary or secondary pulmonary vascular pathology exhibit a relatively fixed pulmonary resistance in that the ability of the muscular resistance vessels to dilate may be significantly reduced. The increase in cardiac output associated with minoxidil therapy, therefore, may well lead to increases in PAP.
In addition, patients with intravascular volume overload as a result of congestive heart failure and impaired renal Significance values refer to differences between the magnitude of change of the pulmonary and peripheral resistance at five days and two months oftreatment. Brackets represent ± I SE sodium excretion might also be at risk for the development of pulmonary hypertension, should the pulmonary vascular capacity be reached. Further increases in cardiac output would not be accomodated by the pulmonary vascular bed and PAP would increase accordingly.
No evidence exists to suggest that this is a specific complication peculiar to minoxidil therapy. Rather, these hemodynamic phenomena can be anticipated with the use of any vasodilator producing an increase in cardiac output. Of the patients previously reported in the literature with pulmonary hypertension noted after the initiation of minoxidil therapy, congestive heart failure and substantial renal impairment were frequent findings. The patients in the present study, however, had neither a history of congestive heart failure nor critically impaired renal function, and these patients were able to tolerate the increase in cardiac output as a result of minoxidil therapy with no change in the pulmonary pressure.
In summary, the present study has demonstrated the potency and efficacy of minoxidil in the treatment of refractory hypertension. The observed increase in cardiac output with minoxidil therapy in the face of concomitant propranolol treatment is primarily due to an increase in stroke volume. Minoxidil reduced both peripheral and pulmonary resistance, but a relatively greater effect was noted in the systemic circuit.
This study has shown that if the reflex increase in heart rate is blocked by propranolol and the increase in stroke volume is minimized by diuretic administration, the potential development of pulmonary hypertension due to large increases in cardiac output can be prevented in patients with initially normal pulmonary hemodynamics. However, in patients with pre-existing pulmonary hypertension, chronic congestive heart failure, or significant renal impairment, careful evaluation for evidence of increasing pulmonary artery pressure as a result of enhanced cardiac output is warranted.
